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Brief Definit ive Report
Actively acquired self-tolerance and immunity 
are opposite processes that pose a central conun-
drum: how do antigen receptors switch between 
signaling lymphocyte death or proliferation when 
engaged by the same antigen in different con-
texts? This problem is exemplified by the sur-
face immunoglobulin antigen receptors (BCRs) 
on mature, recirculating B lymphocytes. Upon 
binding antigen, these receptors trigger multi-
ple rounds of B cell clonal proliferation in the 
context of infection or immunization but in-
duce anergy and apoptosis when they bind 
continuously to antigens that are part of the 
body (self-antigens). Differential amplitude and 
duration of signaling to intracellular calcium, 
PI3 kinase, MAP kinases, and the transcription 
factors NFAT, Jun/Fos, and NF-B corre-
late with differential signaling of growth or 
death by the B cell antigen receptor (Healy 
and Goodnow, 1998). However, as with most 
tolerance/immunity checkpoints, the nature of 
the switch in mature B cells remains unre-
solved because no individual genetic altera-
tion of these pathways has yet been found to 
be sufficient to switch self-antigen–induced 
B cell death into proliferation.
An experiment of nature that provides clues 
to this problem comes from a group of com-
mon human cancers that includes non-Hodgkin’s 
lymphoma and chronic lymphocytic leukemia 
(Rui et al., 2011), in which a clone of B cells 
that has accumulated 30 damaging somatic muta-
tions on average (Morin et al., 2011; Pasqualucci 
et al., 2011) becomes locked in an endless growth 
cycle. It is not yet known how these mutations 
individually or collectively affect the normal re-
sponse to self-antigens, although multiple lines 
of evidence suggest that the growth of human 
B cell malignancies is promoted by continuous 
BCR stimulation by self-antigens (Cleary et al., 
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Self-tolerance and immunity are actively acquired in parallel through a poorly understood 
ability of antigen receptors to switch between signaling death or proliferation of antigen-
binding lymphocytes in different contexts. It is not known whether this tolerance-immunity 
switch requires global rewiring of the signaling apparatus or if it can arise from a single 
molecular change. By introducing individual CARD11 mutations found in human lymphomas 
into antigen-activated mature B lymphocytes in mice, we find here that lymphoma-derived 
CARD11 mutations switch the effect of self-antigen from inducing B cell death into T cell–
independent proliferation, Blimp1-mediated plasmablast differentiation, and autoantibody 
secretion. Our findings demonstrate that regulation of CARD11 signaling is a critical switch 
governing the decision between death and proliferation in antigen-stimulated mature  
B cells and that mutations in this switch represent a powerful initiator for aberrant B cell 
responses in vivo.
© 2012 Jeelall et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
A human lymphoma CARD11 mutation blocks self-antigen 
death and drives growth
To investigate the consequences of acquiring a CARD11 
somatic mutation in antigen-activated normal B cells, we de-
veloped a retroviral gene delivery system to express normal 
or mutant CARD11 in primary antigen-activated B cells 
obtained from transgenic mice (Fig. 1 a). Mature B cells bear-
ing homogeneous antigen receptors against a protein antigen, 
hen egg lysozyme (HEL; Goodnow et al., 1988), were acti-
vated into proliferation by giving IgHEL transgenic mice an 
acute pulse of HEL antigen in vivo followed by stimulation 
of the B cells with antibodies to CD40 in culture for 3 d. 
During this time, the B cells were transduced with bicistronic 
vectors encoding enhanced GFP (EGFP) alone or EGFP and 
WT or different mutant forms of CARD11. We tested four 
CARD11 lymphoma mutations (Fig. 1 a): G123S (Mut3), 
L232LI (Mut10), L251P (Mut2), and D387V (Mut6), with 
the numbers in parentheses referring to the mutations as orig-
inally described (Lenz et al., 2008). After transduction, the 
antigen-activated B cells were transplanted back into synge-
neic Rag1/ mice that either lacked any antigen or CD40 
growth stimuli or that expressed HEL protein in their circu-
lation (Goodnow et al., 1988) so that the B cells were con-
tinuously stimulated by self-antigen (Fig. 1 a).
Because activation of NF-B and c-Jun N-terminal kinase 
(JNK) by the B cell antigen receptor both depend on normal 
CARD11 (Jun et al., 2003), we first compared the activity of 
these signaling pathways in the retrovirally transduced B cells. 
B cells were transduced with retrovirus carrying EGFP only 
(empty vector [EV]), mutant (Mut10), or WT CARD11, or 
a vector encoding a constitutively active IKK- (IKK-*) as 
a positive control. The cells were then washed and cultured 
in media without anti-CD40 for 24 h before sorting EGFP+ 
cells and preparing cell lysates for SDS-PAGE. Compared 
with control B cells expressing WT CARD11 or EGFP only, 
CARD11 Mut10–expressing B cells consistently displayed 
higher phosphorylation of JNK and the p65 (RelA) NF-B 
subunit, whereas IKK-*–expressing cells induced compara-
bly increased phosphorylation of p65 but not of JNK (Fig. 1 b). 
Western blotting of EGFP+ cells for CARD11 showed higher 
levels in cells transduced with CARD11 WT or Mut10 vec-
tors compared with EV controls but no consistent differ-
ence in protein accumulation between cells transduced with 
CARD11 WT or Mut10 (also see Fig. 4 a), indicating that the 
effects of the mutations could not be explained by protein 
expression. In this context, it is notable that CARD11 copy 
number gains also occur in human B cell lymphomas (Morin 
et al., 2011). These results indicate that the lymphoma muta-
tion in CARD11 enhanced signaling to both NF-B and 
JNK pathways in primary, mature B cells.
The transduced B cells were injected into the circulation 
of Rag1-deficient mice that either expressed HEL protein 
(HEL transgenic) or lacked the antigen (nontransgenic). We 
first tested the most potent lymphoma CARD11 mutation, 
Mut10, which originally occurred in a GC-type DLBCL 
1986; Borche et al., 1990; Friedman et al., 1991; Kobayashi 
et al., 1993; Chiorazzi and Ferrarini, 2003; Rui et al., 2011; 
Stevenson et al., 2011). RNA interference screens in tissue 
culture revealed that cells from the ABC-DLBCL (activated 
B cell subtype of diffuse large B cell lymphoma) died when 
components of the antigen receptor signal transduction cas-
cade were depleted (Ngo et al., 2006; Lenz et al., 2008; Davis 
et al., 2010).
One important branch of the BCR signaling cascade ter-
minates on the transcription factor, NF-B, which is activated 
by acute antigen receptor engagement but not chronic recep-
tor engagement by self-antigens (Healy et al., 1997) through 
a pathway whereby PKC phosphorylates and activates 
CARD11 (also called Carma1) to form a CBM (CARD11–
BCL10–MALT1) complex (Jun et al., 2003; Thome, 2004; 
Rawlings et al., 2006). The CBM complex in turn acti-
vates IB kinase (IKK) to phosphorylate and degrade the 
inhibitor of NF-B, IB, allowing NF-B to move to the 
nucleus and cooperate with other transcription factors in 
promoting B cell survival, proliferation, and differentia-
tion (Jun et al., 2003; Thome, 2004; Rawlings et al., 2006; 
Gerondakis and Siebenlist, 2010). 13% of DLBCL cases, in-
cluding ABC and germinal center (GC) types, have acquired 
activating somatic point mutations of various amino acids 
in the coiled-coil regulatory domain of CARD11 that are re-
quired for the proliferation of an ABC-DLBCL lymphoma 
cell line in culture (Lenz et al., 2008). However, many other 
mutations also recur in B cell malignancy that may be needed 
as an ensemble to switch the way B cells respond to chronic 
stimulation (Rui et al., 2011), and indeed dependence on the 
CARD11 branch of the cascade did not extend to the GC 
subtype of diffuse large B cell lymphoma (Ngo et al., 2006; 
Lenz et al., 2008). Likewise, dysregulated NF-B signaling 
on its own was insufficient to initiate B cell growth in ma-
ture, circulating B cells in transgenic mice expressing a con-
stitutively active allele of IKK- (Sasaki et al., 2006), and 
dysregulated expression of the NF-B target gene, Bcl2, de-
layed self-antigen–induced death but did not result in a switch 
into proliferation (Cyster et al., 1994). Collectively, these re-
sults focus the question on what, if any, effects lymphoma 
CARD11 mutations have in isolation on the normal response 
to self-antigens.
In this study, we examine this question using a novel 
retroviral strategy to genetically manipulate a cohort of self-
antigen–binding mature B cells in vivo. Using this system, 
all lymphoma-derived CARD11 mutations tested conferred 
upon CARD11 a potent ability to switch the effect of 
chronic binding of self-antigen from death into inducing 
B cell proliferation and Blimp1-mediated plasmablast dif-
ferentiation and autoantibody production. We conclude 
that regulation of CARD11 is a central switch governing 
the decision between antigen-induced death and growth 
in mature B cells. Mutations in this switch, when paired 
with somatically acquired antigen receptors against self, 
represent a powerful initiator of aberrant B cell growth 
and differentiation.
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Figure 1. A potent CARD11 mutation blocks self-antigen–induced B cell death and promotes extensive proliferation in vivo. (a) Experimental 
strategy to examine the consequences of acquiring different CARD11 coiled-coil domain mutations in normal antigen-activated B cells. (b) Immunoblot for 
phospho/total p65 and phospho/total JNK in cell lysates from EV, WT, Mut10, and constitutively active IKK- (IKK-*)–expressing B cells. Cells cultured in 
media without anti-CD40 for 24 h before EGFP+ cells were sorted. (c) Antigen-specific B cells transduced with the indicated vectors were transplanted into 
Rag1-deficient recipient mice that were either nontransgenic, in which the B cells lacked antigen or CD40 stimuli, or were HEL transgenic, in which the trans-
planted B cells were continuously stimulated by circulating self-antigen. Donor cells in the spleen of recipient mice were analyzed by flow cytometry 5 and  
12 d after transplantation. In the top panels, the transplanted B cells were detected and enumerated as a percentage of spleen cells by their binding of HEL 
antigen and staining for IgMa allotype. The bottom panels are gated on these transplanted B cells and show the percentage that are EGFP+ and their expres-
sion of CD19. (d) The top panel shows the number of EGFP+ B cells that were transplanted into each mouse (input). Bottom panels show mean number ± SEM 
of EGFP+ B cells in the spleen of nontransgenic or HEL transgenic recipient mice on days 5 and 12 (n = 3–6 recipient mice per group and time point; one way 
analysis of variance [ANOVA]: P = 0.0011 and P = 0.0014, respectively). Data are representative of four independent experiments.
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as many CD19+ EGFP+ B cells accumulated in the absence 
of Prdm1 compared with the number of CD19+ cells in con-
trols with WT Prdm1 (Fig. 2 c). Prdm1 deletion nevertheless 
prevented the formation of the large CD19-negative plasma-
blast population, which in the Prdm1+/+ controls contained 
more intracellular EGFP, presumably because of their larger 
cytoplasmic volume. Thus, aberrant proliferation of B cells 
induced by a lymphoma mutation in CARD11 is accom-
panied by efficient induction of Blimp1-mediated plasma 
cell differentiation.
Consistent with CARD11 mutation–induced plasma cell 
differentiation, high concentrations of HEL-binding antibody 
were present in the serum of nontransgenic and HEL trans-
genic Rag1/ recipients of CARD11 Mut10–expressing HEL-
specific B cells (Fig. 2 d). The concentration of anti-HEL IgM 
was comparable with the amount in serum of Ig transgenic 
mice where almost all B cells are HEL specific, which was 
used as a reference, whereas no anti-HEL IgM antibodies 
were detected in the recipients of EV control B cells. These 
results indicate that the CARD11 lymphoma mutation was 
sufficient to overturn B cell tolerance not only to switch self-
reactive cells from death to proliferation but also to induce 
secretion of autoantibodies.
Constitutively active IKK- does not switch  
self-reactive B cells from death into growth
Because CARD11 is an essential scaffold for B cell antigen 
receptor signaling to two diverging pathways, IKK and JNK 
(Jun et al., 2003), we assessed whether an activating mutation 
in IKK itself would have the same effect as the CARD11 
lymphoma mutant. Antigen-activated B cells were transduced 
with a retroviral vector encoding a mutant form of IKK- 
bearing two amino acid substitutions in the activation loop of 
the kinase domain (IKK-*) that results in a constitutively 
active kinase (Sasaki et al., 2006). Although EGFP+ B cells 
expressing IKK-* proliferated spontaneously in tissue culture 
comparably with cells expressing CARD11 Mut10 (Fig. 3 a), 
when the IKK-*–expressing B cells were transplanted into 
recipients, they did not accumulate but instead were elimi-
nated in the presence or absence of HEL self-antigen (Fig. 3, 
b and c). Thus, the death to growth switch caused by lym-
phoma CARD11 mutations is not conferred simply by dys-
regulation of canonical NF-B signaling.
A range of lymphoma CARD11 mutations switch  
self-antigen stimulation from death to proliferation  
and autoantibody secretion
Because the aforementioned in vivo findings focused on a 
single, particularly potent lymphoma CARD11 mutation, 
we next asked whether or not they were a general property 
of lymphoma CARD11 mutations, including weak alleles 
such as Mut3 whose effects on NF-B in cell lines were aug-
mented by antigen receptor signals (Lenz et al., 2008). Trans-
duction and transplantation experiments were performed 
as before (Fig. 1, a and c), except that the antigen-activated 
B cells were transduced with CARD11 Mut6, Mut3, or Mut2, 
(Lenz et al., 2008). We tracked the fate of the transplanted 
B cells in the spleen by flow cytometry using two unique mark-
ers of their antigen receptors, their ability to bind HEL anti-
gen and the presence of an IgMa allotypic epitope (Fig. 1 c; 
Goodnow et al., 1988). EGFP fluorescence within this sub-
set distinguished transduced from nontransduced B cells, 
although the expression of EGFP after CARD11 and the 
IRES (internal ribosome entry site) sequence was lower than 
from the EV control and could not be resolved above auto-
fluorescence in some transduced cells (Fig. 1 c). In HEL trans-
genic Rag1/ recipients, continuous antigen stimulation 
by circulating self-HEL antigen induces the proapoptotic 
Bim protein in mature B cells and triggers apoptosis within 
3 d despite the presence of BAFF (Cyster et al., 1994; 
Enders et al., 2003; Lesley et al., 2004; Thien et al., 2004). 
Consequently, when antigen-specific B cells transduced with 
either EV or WT CARD11 were enumerated in the spleen 5 or 
12 d after transplantation, these were readily detectable in non-
transgenic recipients but had been eliminated from HEL 
transgenic recipients (Fig. 1, c and d). In contrast, CARD11 
Mut10–expressing B cells were not eliminated in HEL trans-
genic recipients, but instead EGFP+ cells persisted and prolif-
erated to very large numbers. In nontransgenic Rag1/ mice 
that lacked HEL protein, the number of EGFP+ B cells ex-
pressing EGFP only or CARD11 WT exhibited little change 
between days 5 and 12 after transfer, whereas those ex-
pressing CARD11 Mut10 proliferated, although the prolifer-
ation of the latter was 6.4 times less than that in the presence 
of HEL antigen (Fig. 1, c and d). Thus, a discrete CARD11 
mutation from a human lymphoma switched the effect of 
chronic antigen receptor stimulation, converting the nor-
mal induction of B cell death into antigen-induced, T cell–
independent proliferation.
CARD11 mutation induces Blimp1-dependent plasma cell 
differentiation and autoantibody production
Compared with the control EGFP+ B cells, most of the 
EGFP+ proliferating cells expressing CARD11 Mut10 main-
tained surface IgM antigen receptor expression but were 
much larger in size (high FSC-A [forward scatter area]) and 
expressed much lower levels of B220 and CD19 (Figs. 1 c 
and 2 a), two B cell lineage markers which are repressed upon 
differentiation into plasma cells (Fairfax et al., 2008). This 
was surprising because physiological proliferation of B cells 
driven by foreign antigen and CD40 stimulation from helper 
T cells normally requires helper T cell–derived cytokines 
like IL-21 to stimulate differentiation into antibody-secreting 
plasma cells. Plasmablast differentiation requires induction 
of Blimp1, encoded by the Prdm1 gene (Fairfax et al., 2008; 
Martins and Calame, 2008). To test whether the human 
lymphoma CARD11 mutations did indeed induce Blimp1-
 dependent differentiation of mature B cells in vivo, we per-
formed retroviral transduction and transfer experiments using 
activated B cells from mice with a B cell–specific deletion of the 
Prdm1 gene (Fig. 2, a–c). CARD11 Mut10–expressing B cells 
lacking Prdm1 still proliferated in vivo, and indeed three times 
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Figure 2. CARD11 mutation induces Blimp1-dependent plasma cell differentiation and autoantibody production. (a) Flow cytometric analysis 
of splenocytes 9 d after transplantation of Prdm1+/+ or Prdm1/ B cells, or no B cells, into Rag1-deficient recipients. The top panels show the percentage 
of transplanted IgM+ B cells in the spleen. The bottom panels are gated on the transplanted B cells and show the percentage of total EGFP+ cells and the 
proportion of these cells that are either EGFP+ CD19+ B cells or EGFP+ CD19 plasmablasts. (b) Fold increase in numbers of EGFP+ B cells normalized to 
the number of EV-expressing Prdm1+/+ B cells detected at day 9 after transfer. (c) Mean number and SEM of EGFP+ CD19+ B cells or EGFP+ CD19 plasma-
blasts in the spleen (n = 3 mice per group and time) on the indicated days after transplantation (one-way ANOVA: P < 0.0001). (d) Amount of anti-HEL 
IgM relative to a standard reference serum from an Ig transgenic mouse, measured by ELISA in serum from transgenic and HEL transgenic mice 11 d after 
transplantation of HEL-specific B cells transduced with the indicated vectors (n = 3 mice per group; one-way ANOVA: P < 0.0001).
alongside cells transduced with Mut10 as a positive control or 
CARD11 WT and EV as negative controls. Western blotting 
of EGFP+ cells established that the expression of the different 
CARD11 mutant proteins was comparable with expression 
of CARD11 WT and approximately twofold the levels of en-
dogenous CARD11 protein in EV EGFP+ B cells (Fig. 4 a). 
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To test the ability of CARD11 mutations to break an 
established state of tolerance in self-reactive B cells and in-
duce proliferation and autoantibody secretion, we repeated 
the aforementioned experiment with anergic B cells har-
vested from IgHEL × HEL double transgenic mice. The state 
of anergy established in IgHEL × HEL B cells is representative 
of anergic B cells with many different self-specificities and 
affinities analyzed in various Ig transgenic mice and of poly-
clonal anergic B cells in human peripheral blood (Goodnow 
and Ohashi, 2012). The self-reactive B cells were main-
tained in the constant presence of HEL antigen during ret-
roviral transduction and then transferred back into HEL 
transgenic recipients (Fig. 4, g and h). CARD11 Mut10 nev-
ertheless broke tolerance in the IgHEL × HEL anergic B cells, 
preventing their elimination in HEL transgenic recipients 
and causing them to proliferate, differentiate into numer-
ous CD19low B220low GFP+ plasmablasts, and produce large 
amounts of anti-HEL autoantibodies.
We also investigated whether the CARD11 mutations 
could provoke IgG autoantibody secretion by normal B cells 
with a diverse repertoire of specificities. B cells from non-
transgenic mice were retrovirally transduced with vectors en-
coding mutant CARD11 or controls encoding WT CARD11, 
mutant IKK-*, or EV. The B cells were transferred into 
Rag1/ recipients and spleen cells, and serum was collected 
12 d later. Compared with the controls, recipients of normal 
B cells expressing mutant CARD11 had higher concentra-
tions of IgM and IgG1 in their sera (Fig. 5, a and b). The in-
duction of serum IgG by the different CARD11 mutants 
correlated with their potency to induce plasmablast accumu-
lation in the same animals, with Mut10 the most potent and 
Mut6 the least potent. IgG antibodies with a diffuse pattern 
of binding to the cytoplasm and nucleus of HEp-2 cells 
(Fig. 5 c) and IgM and IgG antibodies binding to the surface 
of 3T3 mouse fibroblast cells (Fig. 5, d–g) were also selectively 
increased in serum of recipients of B cells expressing mutant 
CARD11. The affinity and pathogenicity of these autoanti-
bodies are nevertheless likely to be low because the recipi-
ents lacked T follicular helper (TFH) cells needed for affinity 
maturation in GCs. It will be interesting in future studies to 
B cells expressing the CARD11 mutants had lower BIM 
levels than B cells expressing CARD11 WT or EV controls, 
with the magnitude of Bim down-regulation inversely pro-
portional to the capacity of the CARD11 mutants to induce 
growth signals (Fig. 4, b and d). Modulation of BIM protein 
could therefore be one mechanism through which B cells 
expressing CARD11 mutant proteins avoid self-antigen–
induced apoptosis.
When approximately equivalent numbers of the trans-
duced B cells were transplanted into HEL transgenic recipients 
(Fig. 4 c), all four lymphoma CARD11 mutations blocked 
self-antigen–induced death of the transferred B cells and co-
operated with chronic antigen stimulation to drive prolifera-
tion (Fig. 4, d and e) and differentiation of most of the GFP+ 
cells into CD19low B220low plasmablasts (Fig. 4 d). In the 
HEL-stimulated cells, the overall numbers of EGFP+ plasma-
blasts were 10–20-fold higher when they expressed CARD11 
Mut2 or Mut10 than with the weaker Mut6 or Mut3 alleles 
(Fig. 4 e), but the presence of HEL antigen enhanced prolif-
eration by a greater multiplier for Mut6 and Mut3 (20- and 
40-fold increase in HEL transgenic compared with non-
transgenic recipients, respectively) compared with Mut2 and 
Mut10 (13- and 4.5-fold increase, respectively). High concen-
trations of serum anti-HEL IgM autoantibodies were detected 
in HEL transgenic recipients in which Mut2- or Mut10-
expressing B cells were transferred but were below the limit of 
detection in recipients of Mut3 or Mut6 B cells, presumably 
because of the lower number of plasma cells formed and 
 antibody neutralization by an excess of circulating self-HEL 
antigen (Fig. 4, e and f). Without self-antigen stimulation in 
nontransgenic recipients, EGFP+ B cells expressing CARD11 
Mut6 or Mut3 did not increase in number measurably rela-
tive to the control B cells over the 12 d, nor did these EGFP+ 
cells increase as a percentage of donor B cells compared with the 
percentage of EGFP+ at the time of transplantation (Fig. 4, c–e). 
Thus, two out of four lymphoma CARD11 mutations tested 
in this assay were insufficient to induce spontaneous B cell 
proliferation in vivo in the absence of ongoing antigen recep-
tor engagement, but all were sufficient to switch the response 
to self-antigen from death into proliferation.
Figure 3. IKK- activating mutation does not switch self-reactive B cell death into proliferation. (a) Number of viable EGFP+ or EGFP B cells 
in tissue culture without antigen or anti-CD40 for 3 d, expressed as a percentage of the starting number on day 3. Numbers are mean ± SEM of three 
independent cultures, and data are representative of five independent experiments. (b) Number of EGFP+ B cells transplanted into each mouse (input).  
(c) Number (mean ± SEM; n = 3 per group) of EGFP+ HEL-binding IgMa+ B cells in the spleen of Rag1-deficient nontransgenic or HEL transgenic mice,  
11 d after transplantation of Ig transgenic B cells transduced with vectors encoding the indicated proteins (one-way ANOVA: P = 0.0080).
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Figure 4. A range of lymphoma CARD11 mutations switch self-antigen–induced B cell deletion into aberrant B cell growth. (a) Immunoblot and 
densitometry analysis of CARD11 in cell lysates from cells expressing control EV and WT CARD11 and lymphoma CARD11 mutants Mut2, Mut3, Mut6, and Mut10. 
Transduced B cells were cultured in media without anti-CD40 for 24 h before EGFP+ cells were sorted. (b) BIM levels expressed as mean fluorescence intensity 
(MFI) measured by flow cytometry analysis of transduced B cells with the indicated vectors (one-way ANOVA: P < 0.0001). (c) Number of input EGFP+ Ig trans-
genic B cells, transduced with vectors encoding the indicated CARD11 alleles, that were transplanted into each recipient mouse in panels d–f. (d) Flow cytometric 
analysis of splenocytes 12 d after transplantation of B cells, transduced with vectors encoding the indicated CARD11 alleles, into HEL transgenic or nontransgenic 
recipients. B220 expression and the percentage of EGFP+ B cells, either as a percentage of all splenocytes or (in parentheses) as a percentage of the transplanted  
B cells, are shown. (e) Mean number (±SEM; n = 3–6 mice per group) of splenic EGFP+ HEL-binding IgMa+ B cells in HEL transgenic or nontransgenic recipients 
12 d after transplantation of transduced B cells (one-way ANOVA: P < 0.0001). (f) Relative units of anti-HEL IgM measured by ELISA in serum collected from non-
transgenic or HEL transgenic mice 11 d after transplantation (n = 3–9 mice per group; one-way ANOVA: P < 0.0001). (g) Mean number (±SEM; n = 3–5 mice per 
group) of splenic EGFP+ HEL-binding IgMa+ B cells in HEL transgenic or nontransgenic recipients, 11 d after transplantation of Ig transgenic or anergic Ig × HEL 
double transgenic B cells (one-way ANOVA: P < 0.0001). (h) Relative units of anti-HEL IgM measured by ELISA on serum collected from nontransgenic or HEL 
transgenic mice 10 d after transplantation (n = 3–5 mice per group; one-way ANOVA: P < 0.0001). Data are representative of three independent experiments.
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switch explains how the mature B cell response to antigen 
ranges from proliferation and plasma cell differentiation on 
the one hand to anergy and death on the other. The data here 
establish that regulation of a single molecule, CARD11, serves 
as the switch between antigen-induced signaling of death or 
proliferation and plasma cell differentiation.
What lies downstream of the CARD11 switch is an in-
triguing question for the future. Activation of NF-B by 
antigen receptor signaling through CARD11 might have been 
predicted to be the mechanism for switching the response 
to self-antigen from death to growth, given that NF-B is es-
sential for activation of numerous B cell survival (e.g., Bcl2, 
BclxL, and Bfl1/A1), growth (e.g., Irf4, Myc, and Cyclin D), 
and differentiation genes (Irf4; Gerondakis and Siebenlist, 2010). 
Enforced expression of Bcl-2 nevertheless only slows the 
rate of self-antigen–induced death in mature B cells but does 
not switch them into proliferation (Cyster et al., 1994). 
investigate the impact of CARD11 mutations in GC B cells 
interacting with TFH cells.
The aforementioned findings demonstrate that a range of 
CARD11 mutations acquired in different human lymphomas 
share the property of switching the mature B cell response to 
continuous stimulation by self-antigens from cell death into 
B cell proliferation, differentiation, and autoantibody secretion. 
In normal mature B cells, continuous self-antigen exposure 
desensitizes antigen receptor signaling to NF-B and JNK 
while preserving signaling for calcium oscillations, NFAT, 
ERK, and Bim induction, and this is thought to explain the 
absence of proliferation and induction of apoptosis in self-
reactive B cells (Healy et al., 1997; Healy and Goodnow, 1998; 
Enders et al., 2003). At the opposite extreme, optimal BCR 
cross-linking by T cell–independent type 2 antigens is suffi-
cient to induce proliferation and plasmablast differentiation. 
It is not known whether a global rewiring or a single pivotal 
Figure 5. Lymphoma CARD11 mutations induce IgG autoantibody production. Normal polyclonal B cells were transduced with vectors encoding 
the indicated CARD11 WT or mutant proteins, constitutively active IKK-*, or EV control. B cells were transferred into Rag1-deficient hosts, and sera  
were collected from the recipients after 12 d. (a and b) ELISA results show amounts of serum IgM (a; one-way ANOVA: P < 0.0001) or IgG1 (b; one-way 
ANOVA: P < 0.0001). (c) Representative HEp-2 staining by IgG in serum from recipients of cells expressing the indicated proteins (n = 4 recipients  
per transfer group). Each image was captured using an identical exposure. Bar, 500 µm. (d–g) Binding of serum IgM (d and e; one-way ANOVA:  
P < 0.0001) and IgG (f and g; one-way ANOVA: P < 0.0001) bound to the surface of mouse 3T3 cells (d and f: representative histogram overlays; e and g: 
mean fluorescence intensity [MFI]; n = 3–4 per group).
 on January 25, 2013
jem
.rupress.org
D
ow
nloaded from
 
Published October 1, 2012
JEM Vol. 209, No. 11 1915
Br ief Definit ive Repor t
MATERIALS AND METHODS
Mice. Rag1/ mice (Mombaerts et al., 1992) and Rag1/ mice expressing 
soluble HEL (ML5 HEL transgenic strain; Goodnow et al., 1988) were used 
as recipients for cell transfer experiments. Donor B cells were obtained from 
the following: (a) antigen-specific B cells were from IgHEL transgenic mice 
bearing rearranged Ig transgenes encoding a HEL-specific antibody or IgHEL × 
ML5 HEL double transgenic mice (Goodnow et al., 1988), (b) Prdm1/  
B cells were from Prdm1Flox/Flox mice (Kallies et al., 2009) crossed to mb1-Cre 
transgenic mice (Hobeika et al., 2006) and littermate controls, and (c) nor-
mal B cells came from WT C57BL/6 mice. Mice were maintained on a 
C57BL/6 background and were housed in specific pathogen–free conditions 
at the Australian Phenomics Facility and the John Curtin School of Medical 
Research. Prdm1Flox/Flox mice crossed to mb1-Cre and littermate controls were 
generated and maintained in accordance with the guidelines of the Walter 
and Eliza Hall Institute Animal Ethics Committee. All experimental mice 
were used between 8 and 16 wk of age. All animals used in this study were 
cared for and used in accordance with protocols approved by the Australian 
National University Animal Experimentation Ethics Committee and the 
current guidelines from the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes.
Retroviral vector and production. Mouse Card11 and Ikbkb genes were 
amplified by Platinum Pfx DNA polymerase (Invitrogen) from mouse spleen 
cDNA and cloned into pBluescript II SK(+) vector. PCR-based site-directed 
mutagenesis was used to introduce gain of function mutations into mouse 
Card11 and Ikbkb. Amplified PCR products were purified and sequenced on 
a 3730xl DNA Analyzer (Applied Biosystems; at the Genome Discovery 
Unit–ACRF Biomolecular Resource Facility, John Curtin School of Medi-
cal Research) according to the manufacturer’s protocol. The mutations cor-
responded to those described by Lenz et al. (2008), and the primers used are 
listed in Table 1. WT and mutant Card11 and Ikbkb genes were transferred 
into pMXs-IRES-GFP vector (provided by T. Kitamura, The University 
of Tokyo, Minato-ku, Tokyo, Japan; Kitamura et al., 2003). The retroviral 
constructs were transfected into Phoenix ecotropic packaging cells (American 
Type Culture Collection) using calcium phosphate precipitation. The super-
natants containing replication-defective retroviral particles were collected and 
frozen at 80°C until used for transduction.
Retrovirus-mediated gene transfer into mouse primary B cells. IgHEL 
transgenic mice were injected intraperitoneally with 5 mg HEL (Sigma-
Aldrich) in PBS (Invitrogen) to provide a pulse of antigen for activation 
in vivo. The spleens were yielded 6 h after the injection, and splenocytes 
were cultured at a density of 4 × 106 cells/ml in complete RPMI containing 
Likewise, enforced expression of Myc using the same retro-
viral transduction assay used here does not inhibit self-
 antigen–induced death nor induce proliferation even when 
combined with p53 inactivation (unpublished data). In-
deed, self-antigen–induced elimination of mature B cells in 
the assay used here remains intact even when the B cells are 
transduced with retrovirus containing constitutively active 
IKK-* vector (Fig. 3 b). The unique ability of CARD11 to 
switch self-reactive B cells from death into growth and plasma 
cell differentiation may stem from CARD11 binding to many 
different signaling proteins (McCully and Pomerantz, 2008), 
which may change the dynamics or balance of NF-B sub-
units that are activated or enlist additional signaling pathways 
such as JNK or p38.
Our findings also provide experimental evidence for the 
long-standing hypothesis that self-reactive antigen receptors, 
which arise frequently by VDJ rearrangements in immature 
B cells (Wardemann et al., 2003) and by V-region hypermuta-
tion in antigen-activated B cells (Shlomchik et al., 1990), 
cooperate with somatic mutations in signaling molecules to 
initiate neoplastic proliferation and production of anti-self 
antibodies (Cleary et al., 1986; Borche et al., 1990; Friedman 
et al., 1991; Kobayashi et al., 1993; Chiorazzi and Ferrarini, 
2003; Rui et al., 2011; Stevenson et al., 2011). As opposed 
to binding microbial antigens, antigen receptors that bind to 
self-antigens provide B cells with an endless source of recep-
tor stimulation. Given the high rate of somatic point muta-
tion in antigen-activated B cells (Liu et al., 2008), the finding 
that single somatic mutations at various sites in the coiled-
coil domain of CARD11 were sufficient to switch antigen 
receptor–induced death into growth, without requiring accu-
mulation of numerous other mutations, identifies CARD11 
as an especially weak link in the normal control of B cell 
malignancy and autoimmunity. The occurrence of CARD11 
mutations together with self-reactive Ig V-regions can be 
expected to have an equally potent influence on therapeutic 
responses and thus should be tested in a broad range of B cell 
malignancies and autoimmune diseases.
Table 1. Primers used for mutagenesis of Card11 and Ikbkb
Primer name Sequence Purpose
CARD11 CS1 5-TTTGCGGCCGCGCCGCCACCATGCCAGGAGGAGGGCCAGCTATG-3 Initial cloning
CARD11 CA1 5-AAAAGCTTCAGCTGGTCCTCGTCCACCCAGATG-3 Initial cloning
CARD11 CS8 5-TTTTAGATCTGCCACCATGCCAGGAGGAGGGCC-3 Retrovirus vector
CARD11 stop A2 5-AAAAGCGGCCGCTCACAGCTGGTCCTCGTCC-3 Retrovirus vector
CARD11 mt2 S 5-GAGAGAAATCAGTCCCCCAAGCTCAAGAATGAC-3 L251P
CARD11 mt2 A 5-GTCATTCTTGAGCTTGGGGGACTGATTTCTCTC-3 L251P
CARD11 mt3 S 5-TCCACCATTGTGGTGGAGGAAAGCCATGAGGGCCTCACAC-3 G123S
CARD11 mt3 A 5-AGTGTGTGAGGCCCTCATGGCTTTCCTCCACCACAATGGT-3 G123S
CARD11 mt6 S 5-GCCTTCCACTCCCGAGTTGAGGCACAGACACAG-3 D387V
CARD11 mt6 A 5-CTGTGTCTGTGCCTCAACTCGGGAGTGGAAGGC-3 D387V
CARD11 mt10 S 5-TCCAACTCGAGATCGACCAGCTCATTAAACACCGACTGAACAAG-3 L232LI
IKK-* S 5-TGAATTCGCCACCATGAGCTGGTCACCGTCCCTCCCA-3 S177E, S181E
IKK-* A 5-AAAACTCGAGTCAGGCGGTTACCGTGAAGCTTCT-3 S177E, S181E
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conjugated to Alexa Fluor 647 (Molecular Probes). FlowJo (Tree Star) was 
used for analysis of flow cytometry data.
ELISA. 96-well plates were coated with 10 µg/ml HEL (Sigma-Aldrich) for 
the anti-HEL ELISA or 0.5 µg/ml rat anti–mouse IgM (BD) and 0.5 µg/ml 
rat anti–mouse IgG1 (BD) for the WT B cell transduction experiments in 
Na carbonate buffer, pH 9.6, and blocked them with 1% BSA (Sigma- 
Aldrich). Serial dilutions of serum from recipient mice were transferred 
to the wells. After incubation and washing, plates were further incubated 
with alkaline phosphatase–conjugated goat anti–mouse IgM (Southern-
Biotech) for the anti-HEL IgM ELISA or with biotin rat anti–mouse IgM 
(BD) followed by streptavidin alkaline phosphatase (Vector Laboratories) and 
alkaline phosphatase goat anti–mouse IgG1 (BD). After washing, the amount 
of enzyme bound to each well with the alkaline phosphatase substrate nitro-
phenyl phosphate was measured. The absorbance of the colored reaction 
product was read at 405 nm by a 96-well plate reader (THERMOmax; 
Molecular Devices). Control sera were used to generate standard calibration 
curves, and the relative units or amounts of test antibody present in sera 
were determined.
Detection of autoantibodies. (a) Diluted sera (1:5 or 1:50) were incubated 
on HEp-2 substrate slides (INOVA), and bound antibodies were detected 
using goat anti–mouse IgG conjugated to Alexa Fluor 488 (Invitrogen). Slides 
were viewed and imaged using an IX71 microscope (Olympus). (b) 3T3 cells 
were incubated with 1:10 diluted sera for 30 min on ice and washed twice, 
and bound IgM or IgG antibodies were detected by APC rat anti–mouse IgM 
(BD) and Alexa Fluor 488 goat anti–mouse IgG, respectively (Molecular 
Probes). Cells were analyzed on an LSR II.
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